VTRO (Vitro Biopharma) Cyclically Adjusted PS Ratio: (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vitro Biopharma Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vitro Biopharma  (AMEX:VTRO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vitro Biopharma Cyclically Adjusted PS Ratio Related Terms


Vitro Biopharma Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Cyclically Adjusted PS Ratio Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.00 15.26 12.49 0.00 0.00

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.00 15.26 12.49 0.00 0.00

VTRO vs : Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Vitro Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitro Biopharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vitro Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vitro Biopharma's Cyclically Adjusted PS Ratio falls into.



Vitro Biopharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vitro Biopharma's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Oct22 is calculated as:

For example, Vitro Biopharma's adjusted Revenue per Share data for the fiscal year that ended in Oct22 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Oct22 (Change)*Current CPI (Oct22)
=0.031/298.0120*298.0120
=0.031

Current CPI (Oct22) = 298.0120.

Vitro Biopharma Annual Data

Revenue per Share CPI Adj_RevenuePerShare
200910 0.000 216.177 0.000
201010 0.001 218.711 0.001
201110 0.001 226.421 0.001
201210 0.001 231.317 0.001
201310 0.002 233.546 0.003
201410 0.007 237.433 0.009
201510 0.005 237.838 0.006
201710 0.013 246.663 0.016
202110 0.024 276.589 0.026
202210 0.031 298.012 0.031

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.